COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL

被引：2
|
作者：
Silva Miguel, L. [1 ]
de Sa, J. [2 ]
Pinheiro, B. [1 ]
Acosta, C. [3 ]
机构：
[1] CISEP Res Ctr Portuguese Econ, Lisbon, Portugal
[2] Ctr Hosp Lisboa, Lisbon, Portugal
[3] Biogen Idec Inc, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2471
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND56
引用
下载
收藏
页码：A758 / A758
页数：1
相关论文
共 50 条
  • [21] Clinical efficacy of delayed-release dimethyl fumarate in Hispanic patients with relapsing-remitting multiple sclerosis: integrated analysis of define and confirm
    Hernandez, L.
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Okwuokeny, M.
    Zhang, A.
    Rana, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E306 - E306
  • [22] COST-UTILITY ANALYSIS OF DISEASE-MODIFYING DRUGS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN IRAN
    Imani, A.
    Golestani, M.
    Tabrizi, J. S.
    Janati, A.
    VALUE IN HEALTH, 2013, 16 (07) : A624 - A624
  • [23] Cost-Utility Analysis Comparing Ocrelizumab vs Rituximab in the Treatment of Relapsing-Remitting Multiple Sclerosis: The Colombian Perspective
    Navarro, Cristian E.
    Betancur, John E.
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 83 - 91
  • [24] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS NATALIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Ma, I
    VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
  • [25] Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England
    Maruszczak, Maciej J.
    Montgomery, Stephen M.
    Griffiths, Matthew J. S.
    Bergvall, Niklas
    Adlard, Nicholas
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (11) : 874 - 885
  • [26] Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis (RRMS) in "non-responders'' to prior treatment with interferon beta
    Fernandez, O.
    Giovannoni, G.
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Yang, M.
    Zhang, A.
    Kurukulasuriya, N. C.
    JOURNAL OF NEUROLOGY, 2014, 261 : S19 - S20
  • [27] Efficacy of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis (RRMS) in "non-responders" to prior treatment with interferon beta
    Fernandez, O.
    Giovannoni, G.
    Fox, R. J.
    Gold, R.
    Phillips, J. T.
    Yang, M.
    Zhang, A.
    Kurukulasuriya, N. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 25 - 25
  • [28] Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM
    Fernandez, Oscar
    Giovannoni, Gavin
    Fox, Robert J.
    Gold, Ralf
    Phillips, J. Theodore
    Potts, James
    Okwuokenye, Macaulay
    Marantz, Jing L.
    CLINICAL THERAPEUTICS, 2017, 39 (08) : 1671 - 1679
  • [29] Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
    Zimmermann, Marita
    Brouwer, Elizabeth
    Tice, Jeffrey A.
    Seidner, Matt
    Loos, Anne M.
    Liu, Shanshan
    Chapman, Richard H.
    Kumar, Varun
    Carlson, Josh J.
    CNS DRUGS, 2018, 32 (12) : 1145 - 1157
  • [30] Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria
    Walter, Evelyn
    Berger, Thomas
    Bajer-Kornek, Barbara
    Deisenhammer, Florian
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 226 - 237
12345